These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 24745925)

  • 1. Hypertension and Atrial Fibrillation: Any Change with the New Anticoagulants.
    Ghiadoni L; Taddei S; Virdis A
    Curr Pharm Des; 2014; 20(39):6096-105. PubMed ID: 24745925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the Working Group 'Hypertension Arrhythmias and Thrombosis' of the European Society of Hypertension.
    Manolis AJ; Rosei EA; Coca A; Cifkova R; Erdine SE; Kjeldsen S; Lip GY; Narkiewicz K; Parati G; Redon J; Schmieder R; Tsioufis C; Mancia G
    J Hypertens; 2012 Feb; 30(2):239-52. PubMed ID: 22186358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New oral anticoagulants and prevention of thromboembolic events in patients with hypertension and atrial fibrillation: an appraisal.
    Borghi C; Paolillo S; Cicero AF; Gargiulo P; Trimarco B; Perrone Filardi P
    J Hypertens; 2017 Apr; 35(4):689-695. PubMed ID: 28033129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices.
    Savelieva I; Bajpai A; Camm AJ
    Ann Med; 2007; 39(5):371-91. PubMed ID: 17701479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stroke risk and antithrombotic strategies in atrial fibrillation.
    Medi C; Hankey GJ; Freedman SB
    Stroke; 2010 Nov; 41(11):2705-13. PubMed ID: 20930160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rivaroxaban versus warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation: A meta-analysis.
    Phan K; Wang N; Pison L; Kumar N; Hitos K; Thomas SP
    Int J Cardiol; 2015 Apr; 185():209-13. PubMed ID: 25797679
    [No Abstract]   [Full Text] [Related]  

  • 8. Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation.
    Piccini JP; Lopes RD; Mahaffey KW
    Curr Opin Cardiol; 2010 Jul; 25(4):312-20. PubMed ID: 20520539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Periprocedural Management of New Oral Anticoagulants in Atrial Fibrillation Ablation.
    Zak M; Castiblanco SA; Garg J; Palaniswamy C; Jacobs LE
    J Cardiovasc Pharmacol Ther; 2015 Sep; 20(5):457-64. PubMed ID: 25827857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Anticoagulants in Atrial Fibrillation: A Primer for the Primary Physician.
    Mookadam M; Shamoun FE; Mookadam F
    J Am Board Fam Med; 2015; 28(4):510-22. PubMed ID: 26152444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Nonvalvular atrial fibrillation: data from the Observatory of Cardiovascular Diseases in the province of Trieste (Italy)].
    Mazzone C; Carriere C; Grande E; Iorio AM; Barbati G; Zecchin M; Serdoz LV; Cioffi G; Tarantini L; Sinagra G; Scardi S; Di Lenarda A
    G Ital Cardiol (Rome); 2015 Jun; 16(6):361-72. PubMed ID: 26156697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of inpatient rivaroxaban versus warfarin on hospital-based outcomes when used for stroke prevention in patients with anticoagulant naïve, new-onset nonvalvular atrial fibrillation.
    Hurley C; Dai S; Sobieraj DM
    Int J Cardiol; 2015 Aug; 192():1-2. PubMed ID: 25981569
    [No Abstract]   [Full Text] [Related]  

  • 13. Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.
    Lip GYH; Skjøth F; Nielsen PB; Kjældgaard JN; Larsen TB
    JAMA Cardiol; 2017 Aug; 2(8):872-881. PubMed ID: 28614582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of rivaroxaban compared with vitamin K antagonists for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis.
    Vamos M; Cappato R; Marchlinski FE; Natale A; Hohnloser SH
    Europace; 2016 Dec; 18(12):1787-1794. PubMed ID: 26797248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A link between hypertension and atrial fibrillation: methods of treatment and prevention.
    Aksnes TA; Kjeldsen SE
    Curr Vasc Pharmacol; 2010 Nov; 8(6):769-74. PubMed ID: 20626338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data.
    Hughes M; Lip GY;
    Thromb Haemost; 2008 Feb; 99(2):295-304. PubMed ID: 18278178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The unappreciated importance of blood pressure in recent and older atrial fibrillation trials.
    Manolis A; Doumas M; Poulimenos L; Kallistratos M; Mancia G
    J Hypertens; 2013 Nov; 31(11):2109-17; discussion 2117. PubMed ID: 24077242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: A retrospective analysis of the rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)].
    Divisón Garrote JA; Escobar Cervantes C
    Semergen; 2016; 42(4):260-2. PubMed ID: 26653339
    [No Abstract]   [Full Text] [Related]  

  • 19. Rivaroxaban in atrial fibrillation cardioversion: insights from the X-VeRT trial.
    Farag M; Gorog DA
    Future Cardiol; 2015 Mar; 11(2):147-51. PubMed ID: 25760874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Feasibility of Treatment with Rivaroxaban for Non-Canonical Indications: A Case Series Analysis.
    Acanfora D; Acanfora C; Scicchitano P; Longobardi M; Furgi G; Casucci G; Lanzillo B; Dentamaro I; Zito A; Incalzi RA; Ciccone MM
    Clin Drug Investig; 2016 Oct; 36(10):857-62. PubMed ID: 27401780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.